ATE360031T1 - Chimäre proteine und anwendungen - Google Patents
Chimäre proteine und anwendungenInfo
- Publication number
- ATE360031T1 ATE360031T1 AT01939973T AT01939973T ATE360031T1 AT E360031 T1 ATE360031 T1 AT E360031T1 AT 01939973 T AT01939973 T AT 01939973T AT 01939973 T AT01939973 T AT 01939973T AT E360031 T1 ATE360031 T1 AT E360031T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- proteins
- disclosed
- trans signal
- chimeric proteins
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17425800P | 2000-01-03 | 2000-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE360031T1 true ATE360031T1 (de) | 2007-05-15 |
Family
ID=22635474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01939973T ATE360031T1 (de) | 2000-01-03 | 2001-01-03 | Chimäre proteine und anwendungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7569663B2 (de) |
| EP (2) | EP1908780B1 (de) |
| JP (1) | JP4723782B2 (de) |
| AT (1) | ATE360031T1 (de) |
| AU (1) | AU2926401A (de) |
| CA (1) | CA2395945C (de) |
| DE (1) | DE60127933T2 (de) |
| ES (1) | ES2391760T3 (de) |
| IL (2) | IL150571A0 (de) |
| WO (1) | WO2001049318A1 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| EA004590B1 (ru) | 1999-01-15 | 2004-06-24 | Байоджен, Инк. | Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина" |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| US6943146B2 (en) * | 2000-05-08 | 2005-09-13 | Biogen Idec Ma Inc. | Method for promoting neovascularization |
| US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| AU2003224950B2 (en) | 2002-04-09 | 2006-09-14 | Biogen Ma Inc. | Methods for treating tweak-related conditions |
| DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| WO2005012363A1 (ja) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | 標的化された炎症惹起剤 |
| AU2006214179A1 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| WO2006122187A2 (en) | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| SI2185589T1 (sl) | 2007-06-01 | 2016-04-29 | University Of Maryland Baltimore | Vezavna sredstva za Fc receptor konstantne regije imunoglobulina |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| JP2012507299A (ja) | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US9221895B2 (en) | 2009-03-13 | 2015-12-29 | The Trustees Of The University Of Pennsylvania | OX40/TRAIL fusion proteins |
| WO2012016073A2 (en) | 2010-07-28 | 2012-02-02 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| EP2621514B1 (de) | 2010-09-28 | 2016-09-21 | KAHR Medical (2005) Ltd | Zusammensetzungen und verfahren zur behandlung von hämatologischen malignomen |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| US20140370012A1 (en) * | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| KR20150058236A (ko) | 2012-08-20 | 2015-05-28 | 글리크닉 인코포레이티드 | 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자 |
| EP2934532B1 (de) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel |
| EP2941438A1 (de) | 2013-01-01 | 2015-11-11 | Kahr Medical Ltd. | Stabile form von signalumwandlungsproteinfusionsproteinen sowie verfahren zur verwendung und herstellung derselben |
| EP2951209A4 (de) | 2013-01-31 | 2016-06-22 | Univ Jefferson | Agonistenfusionsprotein für cd40-ox40 und verwendungen davon |
| EP2950814A4 (de) | 2013-01-31 | 2016-06-08 | Univ Jefferson | Pd-l1- und pd-l2-basierte fusionsproteine und verwendungen davon |
| AU2016227322A1 (en) * | 2015-03-03 | 2017-09-21 | Kahr Medical Ltd | Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases |
| CN106046170B (zh) * | 2015-04-10 | 2020-07-10 | 中国医学科学院药物研究所 | 一种新型trail融合蛋白 |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| IL309260B2 (en) | 2015-07-24 | 2025-01-01 | Gliknik Inc | Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding |
| SG10201913573UA (en) | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| CA3026420A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| EP3491013A1 (de) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155-variante immunmodulatorische proteine und verwendungen davon |
| BR112019009484A2 (pt) | 2016-12-09 | 2019-07-30 | Gliknik Inc | otimização de fabricação de gl-2045, um stradomer multimerizador |
| BR112019009495A2 (pt) | 2016-12-09 | 2019-08-06 | Gliknik Inc | métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| US11267856B2 (en) | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
| IL268198B2 (en) | 2017-02-27 | 2024-10-01 | Shattuck Labs Inc | Tigit- and light-based chimeric proteins |
| JP7244428B2 (ja) | 2017-02-27 | 2023-03-22 | シャタック ラボ,インコーポレイテッド | Vsig8ベースのキメラタンパク質 |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| CN107267619A (zh) * | 2017-07-04 | 2017-10-20 | 武汉波睿达生物科技有限公司 | 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒 |
| EP3694870A1 (de) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4-variante immunmodulatorische proteine und verwendungen davon |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Car t細胞療法のための配列決定法 |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| JP2022512540A (ja) | 2018-08-29 | 2022-02-07 | シャタック ラボ,インコーポレイテッド | Flt3l系キメラタンパク質 |
| BR112022000319A2 (pt) | 2019-07-11 | 2022-03-15 | Kahr Medical Ltd | Heterodímeros e métodos de uso dos mesmos |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| US20240335537A1 (en) * | 2021-08-12 | 2024-10-10 | Baylor College Of Medicine | Engineered soluble decoy receptors to enhance cancer immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| DE69226871T3 (de) * | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US6632789B1 (en) * | 1994-04-29 | 2003-10-14 | The United States Of America As Represented By The Secretary Of The Navy | Methods for modulating T cell responses by manipulating intracellular signal transduction |
| GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
| US6060054A (en) * | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
-
2001
- 2001-01-03 EP EP07006581A patent/EP1908780B1/de not_active Expired - Lifetime
- 2001-01-03 IL IL15057101A patent/IL150571A0/xx unknown
- 2001-01-03 CA CA2395945A patent/CA2395945C/en not_active Expired - Lifetime
- 2001-01-03 AU AU29264/01A patent/AU2926401A/en not_active Abandoned
- 2001-01-03 ES ES07006581T patent/ES2391760T3/es not_active Expired - Lifetime
- 2001-01-03 DE DE60127933T patent/DE60127933T2/de not_active Expired - Lifetime
- 2001-01-03 JP JP2001549685A patent/JP4723782B2/ja not_active Expired - Lifetime
- 2001-01-03 AT AT01939973T patent/ATE360031T1/de not_active IP Right Cessation
- 2001-01-03 EP EP01939973A patent/EP1248645B1/de not_active Expired - Lifetime
- 2001-01-03 US US10/169,686 patent/US7569663B2/en not_active Expired - Lifetime
- 2001-01-03 WO PCT/US2001/000145 patent/WO2001049318A1/en not_active Ceased
-
2002
- 2002-07-03 IL IL150571A patent/IL150571A/en active IP Right Revival
Also Published As
| Publication number | Publication date |
|---|---|
| EP1248645A4 (de) | 2003-08-06 |
| EP1248645A1 (de) | 2002-10-16 |
| IL150571A0 (en) | 2003-02-12 |
| JP4723782B2 (ja) | 2011-07-13 |
| CA2395945A1 (en) | 2001-07-12 |
| EP1248645B1 (de) | 2007-04-18 |
| DE60127933D1 (de) | 2007-05-31 |
| JP2003521485A (ja) | 2003-07-15 |
| IL150571A (en) | 2010-11-30 |
| AU2926401A (en) | 2001-07-16 |
| US7569663B2 (en) | 2009-08-04 |
| EP1908780B1 (de) | 2012-08-15 |
| DE60127933T2 (de) | 2008-02-07 |
| US20030216546A1 (en) | 2003-11-20 |
| WO2001049318A1 (en) | 2001-07-12 |
| CA2395945C (en) | 2013-12-24 |
| ES2391760T3 (es) | 2012-11-29 |
| EP1908780A1 (de) | 2008-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60127933D1 (de) | Chimäre proteine und anwendungen | |
| UA90657C2 (ru) | Ловушки vegf и их терапевтические применения | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| AU2003228962A1 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| EP2277889A3 (de) | Fusionsproteine von Albumin und Interferon beta | |
| WO2005021579A3 (en) | Epo mimetic peptides and fusion proteins | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| CY1108489T1 (el) | Παραγωγη τετρασθενων αντισωματων | |
| DE602004011770D1 (de) | Fusionsproteine | |
| ATE363535T1 (de) | Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend | |
| EP1832599A3 (de) | Albuminfusionsproteine | |
| EP1005376A4 (de) | Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| WO2005002526A3 (en) | Method and compositions for treatment of viral infections | |
| EP1536006A4 (de) | Krebsantigene und deren nutzung | |
| DE60037978D1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
| WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
| WO2005054286A3 (en) | Interleukin-11 fusion proteins | |
| WO2003014293A3 (en) | Novel polypeptide analogs and fusions and their methods of use | |
| WO2002079222A3 (en) | Fusion proteins for specific treatment of cancer and auto-immune diseases | |
| ATE278011T1 (de) | Human dnase ii | |
| ATE230027T1 (de) | Menschliche dnase i varianten | |
| MXPA03010739A (es) | Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas. | |
| WO2004011638A3 (en) | Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures | |
| WO2002050116A3 (en) | Adhesion molecule protein | |
| AU2001288284A1 (en) | 14189, a human kinase and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |